Impax Asset Management Group plc lifted its stake in Chemed Co. (NYSE:CHE – Free Report) by 19.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 317,943 shares of the company’s stock after purchasing an additional 51,974 shares during the period. Impax Asset Management Group plc owned approximately 2.10% of Chemed worth $172,510,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Chemed by 3.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 100,604 shares of the company’s stock worth $58,828,000 after acquiring an additional 3,269 shares in the last quarter. Principal Securities Inc. acquired a new stake in Chemed in the fourth quarter valued at $51,000. Calton & Associates Inc. purchased a new position in shares of Chemed in the fourth quarter valued at $227,000. Teacher Retirement System of Texas raised its stake in shares of Chemed by 9.5% during the 4th quarter. Teacher Retirement System of Texas now owns 5,604 shares of the company’s stock worth $3,277,000 after buying an additional 486 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Chemed by 41.5% in the 4th quarter. BNP Paribas Financial Markets now owns 16,037 shares of the company’s stock worth $9,378,000 after buying an additional 4,706 shares in the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.
Wall Street Analyst Weigh In
Separately, Royal Bank of Canada cut their target price on shares of Chemed from $712.00 to $697.00 and set an “outperform” rating for the company in a research report on Tuesday, May 21st.
Insiders Place Their Bets
In related news, Director Patrick P. Grace sold 284 shares of the company’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $540.98, for a total value of $153,638.32. Following the completion of the transaction, the director now directly owns 3,270 shares in the company, valued at $1,769,004.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $569.63, for a total value of $1,139,260.00. Following the transaction, the chief executive officer now directly owns 105,735 shares of the company’s stock, valued at approximately $60,229,828.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Patrick P. Grace sold 284 shares of Chemed stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $540.98, for a total value of $153,638.32. Following the completion of the transaction, the director now owns 3,270 shares in the company, valued at approximately $1,769,004.60. The disclosure for this sale can be found here. Insiders have sold a total of 5,315 shares of company stock valued at $3,006,573 in the last quarter. 3.32% of the stock is currently owned by company insiders.
Chemed Trading Up 0.6 %
Shares of NYSE:CHE traded up $3.35 on Friday, hitting $577.15. The company had a trading volume of 1,079 shares, compared to its average volume of 85,318. The company has a market cap of $8.74 billion, a PE ratio of 30.91, a PEG ratio of 2.39 and a beta of 0.43. The business has a 50 day moving average of $560.85 and a 200 day moving average of $580.27. Chemed Co. has a 52-week low of $492.84 and a 52-week high of $654.62.
Chemed (NYSE:CHE – Get Free Report) last released its quarterly earnings results on Wednesday, July 24th. The company reported $5.47 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.59 by ($0.12). The firm had revenue of $595.88 million for the quarter, compared to analyst estimates of $599.20 million. Chemed had a return on equity of 29.21% and a net margin of 12.88%. Chemed’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same period in the prior year, the business earned $4.71 earnings per share. As a group, equities analysts predict that Chemed Co. will post 21.77 EPS for the current year.
Chemed Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, August 30th. Shareholders of record on Monday, August 12th were issued a $0.50 dividend. The ex-dividend date of this dividend was Monday, August 12th. This is an increase from Chemed’s previous quarterly dividend of $0.40. This represents a $2.00 annualized dividend and a yield of 0.35%. Chemed’s payout ratio is 10.76%.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Featured Stories
- Five stocks we like better than Chemed
- About the Markup Calculator
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- How to invest in marijuana stocks in 7 steps
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- 3 REITs to Buy and Hold for the Long Term
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.